Amgen Inc. Stock
€358.95
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Amgen
sharewise wants to provide you with the best news and tools for Amgen, so we directly link to the best financial data sources.
Financials
News
Zai Lab Q2 Earnings Call Highlights
Key Points
- Interested in Zai Lab Limited Unsponsored ADR? Here are five stocks we like better.
- Q2 net product revenue rose 11% sequentially to $105.8 million, supported by VYVGART volume
Amgen Q2 Earnings Call Highlights
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen reported strong second-quarter results, with revenue exceeding $10 billion, up 10% year over year, and raised its
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen said its strong first-quarter results support the idea that 2026 could be a “springboard year”, with revenue up
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen highlighted strong first-quarter performance, with revenue up 6% year over year and non-GAAP EPS up 5%
Zai Lab Q1 Earnings Call Highlights
Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
Demand for GLP-1 drugs is exploding. While medicines in this category traditionally treated diabetes, they are now being approved to manage other conditions, including obesity and obstructive sleep
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
Amgen (NASDAQ: AMGN) is betting that the convenience of its weight loss treatment will make it a winner, and it might be right. Its candidate MariTide is a monthly injection that aims to directly
How Safe Is Amgen's Dividend?
Amgen (NASDAQ: AMGN) has been grabbing headlines lately, and not always for the right reasons. The company is currently engaged in a battle with the U.S. Food and Drug Administration (FDA), which
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Does the established stability of a pharmaceutical giant outweigh the explosive growth potential of a specialized cancer fighter? Investors choosing between Amgen (NASDAQ:AMGN) and Iovance
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Deciding between a pharmaceutical giant and a niche medical innovator depends on your risk tolerance. Amgen (NASDAQ:AMGN) and NovoCure (NASDAQ:NVCR) offer vastly different paths to potential growth
Amgen: A Biotech Giant's Path to Recovery and Growth
Explore the exciting world of Amgen (NASDAQ: AMGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market
2 Dividend Stocks to Double Up On Right Now
Equity markets have handled the economic uncertainty and geopolitical instability we have seen in recent months admirably well so far. The S&P 500 is up 7% year to date. However, we may not be
Better Weight Loss Stock: Novo Nordisk Vs. Amgen
The weight-loss market has become one of the most active therapeutic areas in the pharmaceutical industry over the past few years. And based on analyst projections, it will continue growing at a